Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor's boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor. In a Phase 1 clinical trial, AN3365 was shown to be safe and well tolerated. Under the agreement, GSK has 90 days to review the data and decide whether to exercise its option to license the compound. If GSK exercises its option, Anacor would receive a $15 million payment, and potentially would receive commercialization milestones and royalties on product sales.

“AN3365 is a first-in-class antibiotic that demonstrates potent activity across a wide spectrum of Gram-negative bacteria, including those resistant to many other antibiotics.”

"We are pleased with the results of the Phase 1 trial," said David Perry, CEO of Anacor Pharmaceuticals. "AN3365 is a first-in-class antibiotic that demonstrates potent activity across a wide spectrum of Gram-negative bacteria, including those resistant to many other antibiotics."

SOURCE Anacor Pharmaceuticals